A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel. 2014

Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
School of Pharmacy, Second Military Medical University, Shanghai, PR China; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian, PR China.

A novel polyethylene glycol 400 (PEG400) mediated lipid nanoemulsion as drug-delivery carrier for paclitaxel (PTX) was successfully developed. The formulation comprised a PEG400 solution of the drug (25mg/mL) that would be mixed with commercially 20% lipid emulsion to form PTX-loaded nanoemulsion (1mg/mL) prior to use. This two-vial formulation of PTX-loaded lipid nanoemulsion (TPLE) could significantly reduce extraction of reticuloendothelial system (RES) organs and increase tumor uptake, and exhibited more potent antitumor efficacy on bearing A2780 or Bcap-37 tumor nude mice compared to conventional PTX-loaded lipid nanoemulsion (CPLE). TPLE did not cause haematolysis and intravenous irritation response yet, and showed the same cytotoxicity against HeLa cells as Taxol®, and its LD50 was 2.7-fold higher than that of Taxol®, suggesting its good safety and druggability. In addition, TPLE displayed distinctly faster release of PTX, a greater proportion of PTX in phospholipids layer and a smaller share in oil phase than CPLE. From the Clinical Editor: This study demonstrates the feasibility and potential advantage of a novel PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in clinical application for the cancer therapy. BACKGROUND This team of investigators convincingly demonstrates the feasibility and potential advantage of a PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in cancer therapy, documenting superior safety and faster release of PTX compared to commercially available formulations.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion

Related Publications

Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
January 2015, International journal of nanomedicine,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
March 2016, Journal of controlled release : official journal of the Controlled Release Society,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
June 2018, Macromolecular bioscience,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
January 2021, International journal of biological macromolecules,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
July 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
January 2016, Recent patents on drug delivery & formulation,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
January 2019, PloS one,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
March 1993, Zentralblatt fur Pathologie,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
March 2001, International journal of pharmaceutics,
Xiaolong Jing, and Li Deng, and Baoan Gao, and Lin Xiao, and Yingying Zhang, and Xingfa Ke, and Jianhao Lian, and Qiang Zhao, and Lulu Ma, and Jianzhong Yao, and Jianming Chen
January 2013, BioMed research international,
Copied contents to your clipboard!